On this page
Two GLP-1 pills are now FDA-approved for weight loss: oral semaglutide, sold as the Wegovy pill, and orforglipron (Foundayo). The semaglutide pill is a peptide that has to be taken fasting; orforglipron is a small molecule with no food or water rules. Injectable GLP-1s still produce the highest average weight loss, but the gap is closing.
For years the only way to take a GLP-1 was by weekly injection. That has changed. Two GLP-1 pills are now approved for weight loss in the United States, and they take very different routes to get there.
Pills are easier to start and need no needles. The trade-off lives in the details, like how the drug is absorbed, when you can eat, and how much weight comes off on average. Here is where each oral option stands today.
Oral GLP-1 options today
Until recently, every GLP-1 used for weight loss was an injection. Wegovy (semaglutide) and Zepbound (tirzepatide) are still the most prescribed, and they remain the benchmark for results. The oral side of the class now has three names worth knowing.
- Rybelsus is oral semaglutide at 7 mg and 14 mg, approved in 2019 for type 2 diabetes, not weight loss.
- The Wegovy pill is a higher 25 mg dose of oral semaglutide that the FDA cleared for chronic weight management in December 2025.
- Orforglipron, sold as Foundayo, is a once-daily small-molecule pill from Eli Lilly, FDA-approved for weight management in April 2026.
According to the FDA, the Wegovy pill was the first oral GLP-1 receptor agonist cleared specifically for weight loss in December 2025, and orforglipron followed a few months later as the first that works without any food or water timing. If you want the wider picture of how this class behaves, our guide on how GLP-1s work covers the biology.
Oral semaglutide for weight loss
Semaglutide is a peptide, and peptides are hard to absorb through the gut because digestion tends to break them apart. The tablet gets around that with an absorption enhancer called SNAC, which helps a small amount of the drug cross the stomach lining. That chemistry comes with rules. You take the pill first thing in the morning on an empty stomach, with no more than about 4 ounces of plain water, then wait at least 30 minutes before eating, drinking, or taking other medicines.
The lower-dose version, Rybelsus, has treated type 2 diabetes since 2019. The open weight-loss question was whether a higher dose could match the shot. Novo Nordisk's OASIS program tested 25 mg oral semaglutide in adults with obesity, and in the OASIS 4 trial reported in 2025, people who stuck with it lost about 16.6% of their body weight. The FDA approved that dose as the Wegovy pill in December 2025, with results in the same range as injectable Wegovy. The brand-by-brand details sit in our semaglutide guide.
Orforglipron: the small-molecule pill
Orforglipron takes a different approach. It isn't a peptide at all but a small molecule, which means it survives digestion on its own. No SNAC, no fasting window, no 4-ounce water limit. You can take it any time of day, with or without food. For anyone who finds the semaglutide timing fiddly, that convenience is the headline.
The efficacy data come from Eli Lilly's phase 3 program: the ATTAIN trials for obesity and ACHIEVE for type 2 diabetes. In the ATTAIN-1 trial published in the New England Journal of Medicine in 2025, the highest orforglipron dose produced roughly 12% average weight loss over 72 weeks. That is real, though below what the strongest injectables deliver. The FDA approved orforglipron as Foundayo in 2026. For where it fits among the next wave of weight-loss drugs, see our look at what's coming next.
Pills vs. injections: efficacy and trade-offs
Convenience and results pull in opposite directions right now. Pills win on ease, with no needles, no weekly injection, and orforglipron drops the food-timing hassle entirely. Injections still win on the scale. Injectable tirzepatide (Zepbound) produced about 21% average weight loss in its SURMOUNT-1 trial in 2022, the high mark for the class, and injectable semaglutide lands near 15%. The rough hierarchy by average weight loss today looks like this.
- Injectable tirzepatide (Zepbound) sits at the top, around 20% or more.
- Semaglutide, oral or injectable, runs roughly 15% to 16%.
- Orforglipron (Foundayo) comes in near 12%.
So the oral semaglutide pill nearly matches its own injection, while orforglipron trades some weight loss for the easiest routine of any of them. None of that makes a pill the obvious pick, or a shot the obvious pick. It depends on what you will actually take consistently, what your insurance covers, and how your body tolerates the medication.
GLP-1s are not for everyone. They are not appropriate if you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, or if you are pregnant or breastfeeding. Be wary, too, of any site selling oral GLP-1 pills with no medical visit. A real prescription follows a clinician reviewing your history.
If you are weighing a pill against a shot, the most useful next step is a conversation with a clinician who can match the option to your history and to what you will keep up with month after month.